A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms

Second-generation mammalian target of rapamycin (mTOR) inhibitors such as CC-223 may have theoretical advantages over first-generation drugs by inhibiting TOR kinase in mTOR complex 1 (mTORC1) and 2 (mTORC2), potentially improving clinical efficacy for well-differentiated neuroendocrine tumors (NET)...

全面介紹

Na minha lista:
書目詳細資料
發表在:PLoS One
Main Authors: Wolin, Edward, Mita, Alain, Mahipal, Amit, Meyer, Tim, Bendell, Johanna, Nemunaitis, John, Munster, Pam N., Paz-Ares, Luis, Filvaroff, Ellen H., Li, Shaoyi, Hege, Kristen, de Haan, Hans, Mita, Monica
格式: Artigo
語言:Inglês
出版: Public Library of Science 2019
主題:
Research Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6748410/
https://ncbi.nlm.nih.gov/pubmed/31527867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0221994
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍